SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

TSLA is under significant downward pressure as investors rotate out of growth stocks amid geopolitical instability and skepticism regarding the execution of its latest AI and infrastructure initiatives. The community remains deeply divided, with some buyers viewing the current price action as a long-term accumulation opportunity, while others express frustration over the stock's recent technical breakdown and the company's dependency on speculative future projects.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as investors weigh strong client asset growth and platform upgrades against concerns regarding fee compression and potential market share disruption from AI-driven fintech competitors. The community is actively debating the company's long-term stability and its recent move into private markets, while many traders remain focused on its technical performance and earnings trajectory.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending due to intense community debate surrounding the administration's aggressive stance on Iran and controversial threats involving the use of federal agents at airports. Investors and social media participants are heavily polarized, with vocal discourse focused on the company's financial volatility, the geopolitical implications of the unfolding conflict, and the broader influence of figures like Elon Musk in the current administration's policy decisions.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and price appreciation following its recent NYSE listing, with investors actively debating whether the high premium over its reported net asset value is justified by its exclusive exposure to high-profile private AI companies like Anthropic and OpenAI. Community discussion is dominated by the impact of a mandatory six-month lockup period on the majority of shares, which has created a tight float and sparked intense speculation about potential for further momentum or a sharp correction.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

Crane Harbor Acquisition Corp. is trending as shareholders recently approved its merger with Xanadu Quantum Technologies, a milestone expected to establish the first publicly traded photonic quantum computing company under the ticker XNDU. Community discussion is heavily focused on the deal's potential for a low-float short-term squeeze, strategic partnerships with major tech industry leaders, and potential government funding support.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently drawing significant community attention as investors debate the impact of new institutional partnerships, exchange-traded fund developments, and the potential for long-term tokenization utility. While many in the community express deep frustration over recent price volatility, others are actively using the current market climate to accumulate positions, citing the project's role in institutional blockchain infrastructure as a primary driver for a future rebound.

Sui is an innovative layer-1 blockchain platform crafted to meet the demands of global adoption, providing a secure, robust, and scalable development environment. Rooted in a unique object-centric data model and fortified by the trusted Move programming language, Sui is engineered to tackle the inefficiencies found in current blockchain frameworks.  In addition to its solid technical underpinnings, Sui places a strong emphasis on user experience, aiming to remove common barriers encountered in blockchain interactions. Through groundbreaking features such as zkLogin, sponsored transactions, and programmable transaction blocks, Sui sets a new standard for user accessibility and friendliness within Web3 applications.  Unique elements of Sui Sui’s innovative architecture ensures swift transactions with stable fees and high throughput through horizontal scaling. Its object-oriented design offers deep composability for developers, enabling tailored object types with network-wide compatibility. This revolutionizes asset and protocol collaboration, fostering product innovation.  The platform's object-oriented approach dramatically improves transaction processing, enabling parallel execution and faster completion times. Additionally, unique consensus requirements expedite transaction finalization while maintaining stability. Sui prioritizes overcoming Web3 adoption barriers, offering native tools like zkLogin and sponsored transactions for wallet onboarding and fee management.  Move integration into Sui's data model combines innovation with security, mitigating common exploits found in smart contract languages. This empowers developers and users with a secure and intuitive platform, accelerating the evolution of Web3 applications.  About the Sui token The SUI token serves four primary functions within the Sui ecosystem: Proof-of-stake participation - Sui implements a delegated proof-of-stake mechanism, rewarding honest behavior by validators and SUI token holders who stake with them. Gas fee payments - SUI tokens cover gas fees for executing transactions and storing data onchain. Application utility - SUI is a versatile asset, integral to various applications within Sui’s ecosystem, including decentralized exchanges, lending platforms, gaming, and more. Governance - The SUI token empowers holders to participate in on-chain voting on significant matters like protocol upgrades and platform changes, shaping the future of Sui.  Additionally, the Sui storage fund ensures fair compensation for validators by distributing stake rewards over time and covering storage costs for previously stored on-chain data. This tokenomic strategy promotes indefinite data storage while maintaining fair compensation for validators, fostering long-term sustainability.

SUI is experiencing significant retail momentum as investors accumulate the asset, viewing it as a potential high-growth alternative to established Layer 1 protocols. The community is actively debating its long-term deflationary mechanics and the impact of upcoming institutional ETF launches, with many using recent price volatility to aggressively build their positions.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is trending as market sentiment surges following high-profile industry discussions regarding the platform's role in the decentralized AI revolution. Investors are closely monitoring the upcoming supply halving and the rapid expansion of network subnets, which many in the community view as foundational infrastructure for the long-term AI-crypto convergence.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The Melania Crypto token is facing intense community backlash and extreme volatility, with market participants widely labeling it a high-risk "pump-and-dump" scam that has suffered a massive decline from its initial peak. Investors are actively debating the legitimacy of the project, with many expressing regret over losses and warning others to avoid the asset due to its association with a series of controversial financial ventures linked to the Trump family.

Shell Plc engages in the business of producing oil and natural gas. It operates through the following segments: Integrated Gas, Upstream, Marketing, Chemicals and Products, Renewables and Energy Solutions, and Corporate. The Integrated Gas segment includes liquefied natural gas, and conversion of natural gas into gas-to-liquids fuels. The Upstream segment focuses on exploration and extraction of crude oil, natural gas, and natural gas liquids. The Marketing segment is involved in mobility, lubricants, and sectors and decarbonization businesses. The Chemicals and Products segment consists of chemicals manufacturing plants with marketing network and refineries, which turn crude oil and other feedstocks into a range of oil products. The Renewables and Energy Solutions segment provides renewable power generation, marketing, trading, and optimizing power and pipeline gas, as well as carbon credits and digitally enabled customer solutions. The Corporate segment covers non-operating activities supporting Shell such as holdings, treasury organization, self-insurance activities, and headquarters and central functions. The company was founded in February 1907 and is headquartered in London, the United Kingdom.

Shell Plc - ADR (Representing - Ordinary Shares)

Shell is gaining traction as investors weigh geopolitical risks in the Middle East against the company's robust capital return program, including consistent multi-billion dollar share buybacks. The community is actively debating the stock's role as a hedge against energy supply volatility, while also tracking its strategic expansion in the LNG market and ongoing efforts to divest non-core chemical assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies

SRPT plans FDA filings to convert Amondys 45 and Vyondys 53 to full approvals, leveraging new data despite a missed endpoint in its confirmatory study.

<ul class="summary-bullets"><li>With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.&nbsp;</li><li>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year.</li><li>Earlier this week, Sarepta also said that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its DMD gene therapy Elevidys.</li></ul><p>Sarepta Therapeutics (SRPT) said on Thursday that it intends to make certain submissions to the U.S. Food and Drug Administration regarding two of its Duchenne muscular dystrophy therapies by the end of April, in a move applauded by Wall Street.</p><p>Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals, with the help of data from a confirmatory late-stage study.</p><p>The company said that the FDA has confirmed that data from the trial can be submitted as part of the application. However, the adequacy of the data to support conversion to traditional approval will be a matter of review, the company said.</p><h2 class="st-heading-2">Analyst Takeaway</h2><p>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year. The analyst added that it also signals positive FDA feedback during a meeting, pointing to potential sNDA approval.</p><p>The firm reiterated an ‘Outperform’ rating on Sarepta with a price target of $37 on the shares.</p><h2 class="st-heading-2">About Vyondys And Amondys</h2><p>Vyondys 53 and Amondys 45 are both FDA-approved, weekly intravenous antisense oligonucleotide therapies from Sarepta for Duchenne muscular dystrophy (DMD), a severe, progressive genetic disorder primarily affecting young boys, characterized by muscle degeneration. Both therapies now have an accelerated approval.</p><p>While Accelerated Approval (AA) allows faster market access for drugs treating serious conditions, based on surrogate endpoints that likely predict clinical benefit, Traditional Approval requires direct evidence of clinical benefit. Accelerated approval requires post-marketing confirmatory trials to prove clinical efficacy to prevent the approval from being withdrawn.</p><p>With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.</p><h2 class="st-heading-2">Sarepta’s Update For Elevidys</h2><p>Earlier this week, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-shares-rise-as-company-begins-enrollment-in-gene-therapy-safety-enhancement-study/cZ3PezERIQd">said</a> that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.</p><p>FDA-approved Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around SRPT stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> is down 79% over the past 12 months.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst

Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals. 

Equity

Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals. 


Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Oppenheimer

Oppenheimer reiterated an "outperform" rating and set a $37.00 price target on shares of Sarepta Therapeutics in a research report on Thursday...

Sarepta Provides Regulatory Update on AMONDYS 45 and VYONDYS 53

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided an update on its ongoing regulatory interactions with the U.S. Food and Drug...

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.

KROS: Is the Discount Book Value a Value Trap?

Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.

KROS Stock: What to Know About Rinvatercept in DMD

Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.

SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study

Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.

<ul class="summary-bullets"><li>Sarepta is looking to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.</li><li>Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li><li>While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</li></ul><p>Shares of Sarepta Therapeutics, Inc. (SRPT) edged up nearly 1.5% on Monday after the company said that screening and enrollment are underway in a cohort of its study, aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.</p><p>Data from the cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks of acute liver injury and acute liver failure associated with Elevidys in DMD patients who cannot walk.</p><h2 class="st-heading-2">Gene Therapy Study Details</h2><p>Sarepta is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-screening-and-enrollment-are-underway-endeavor">looking</a> to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.</p><p>Patients enrolled in the cohort will be administered peri-infusion sirolimus 14 days before Elevidys administration and will continue to receive it for 12 weeks after Elevidys, the company said.</p><p>Elevidys is the only approved gene therapy for Duchenne, a severe, progressive genetic muscle-wasting disease, primarily affecting young boys.</p><p>Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</p><h2 class="st-heading-2">Street Consensus</h2><p>Last week, Mizuho raised the firm's price target on Sarepta to $31 from $26 and kept an ‘Outperform’ rating on the shares, while Citi raised the its price target on Sarepta to $9 from $8 and kept a ‘Sell’ rating on the shares.</p><p>According to data from Koyfin, the average 12-month price target on the stock is $20.61, representing a potential upside of about 24% from current trading levels, as of the time of writing.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around SRPT stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> has fallen nearly 84% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-halts-v3-supercharger-production-in-new-york/cZ3PEpcRIQb">Tesla Halts V3 Supercharger Production In New York In Favor Of Faster, Rival EV-Compatible Variant</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study

Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy. 

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced screening and enrollment are underway in Cohort 8 of ENDEAVOR (Study 9001-103...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRPT News

SRPTSarepta Therapeutics Inc